genic shock in patients with AMI comes from the GUSTO I trial in which 2972 (7.2%) of 41,021 patients were found to have cardiogenic shock. 2 Whereas mortality rates for such patients had been reported to be as high as 80% in the prethrombolytic era, 3 patients with cardiogenic shock in GUSTO I had a 55% 30-day mortality rate. 2 Whether this reflects a beneficial effect of thrombolysis or the selection of healthier patients for entry into a clinical trial has been debated.
Background Cardiogenic shock complicating acute myocardial infarction (AMI) remains the leading cause of death in patients hospitalized with AMI. Although several studies have demonstrated the importance of establishing and maintaining a patent infarct-related artery, it remains unclear as to whether intra-aortic balloon counterpulsation (IABP) provides incremental benefit to reperfusion therapy. The purpose of this study was to determine whether IABP use is associated with lower in-hospital mortality rates in patients with AMI complicated by cardiogenic shock in a large AMI registry.
Methods
We evaluated patients participating in the National Registry of Myocardial Infarction 2 who had cardiogenic shock at initial examination or in whom cardiogenic shock developed during hospitalization (n = 23,180).
Results
The mean age of patients in the study was 72 years, 54% were men, and the majority were white. The overall mortality rate in all patients who had cardiogenic shock or in whom cardiogenic shock developed was 70%. IABP was used in 7268 (31%) patients. IABP use was associated with a significant reduction in mortality rates in patients who received thrombolytic therapy (67% vs 49%) but was not associated with any benefit in patients treated with primary angioplasty (45% vs 47%). In a multivariate model, the use of IABP in conjunction with thrombolytic therapy decreased the odds of death by 18% (odds ratio, 0.82; 95% confidence interval, 0.72 to 0.93). counterpulsation (IABP), by augmenting perfusion pressure, could also enhance coronary thrombolysis induced by intravenous administration of recombinant tissue plasminogen activator (r-TPA). 8, 9 Preliminary clinical studies support the concept that IABP enhances thrombolysis in the setting of AMI and may prevent reocclusion. [10] [11] [12] [13] The purpose of this study was to determine whether the use of IABP is associated with a beneficial effect in patients with AMI complicated by cardiogenic shock. To examine this question, we performed a retrospective cohort study with the National Registry of Myocardial Infarction 2 (NRMI 2), a large registry of patients with AMI.
Conclusions

Methods
Data sources
NRMI 2 is a prospective, observational study sponsored by Genentech, Inc (South San Francisco, Calf). NRMI 2, which was initiated in June 1994, contains data abstracted from the charts of patients with AMI admitted to registry hospitals. The completed case report form is forwarded from the registry hospital to an independent central data collection center (ClinTrials Research, Inc, Lexington, Ky) for processing and analysis. The data collection center used double-key entry to add data from each case report form to the database. Electronic data checks were performed to detect internal inconsistencies, omissions, errors, and out-of-range variables. Demographic, historic, and hospital course variables have been shown to be comparable to the Cooperative Cardiovascular Project database, which has centralized chart abstraction. 14 
Patient inclusion and data collection
Patients were eligible for entry into NRMI 2 if diagnosed with AMI at a participating hospital. The method of diagnosis of AMI was defined by the study protocol as (1) a patient history and presentation suggestive of AMI accompanied by (a) total creatinine kinase greater than or equal to twice the upper limit of hospital laboratory normal or creatinine kinase-MB greater than or equal to the upper limit of hospital laboratory normal, (b) electrocardiographic evidence of AMI, or (c) in the absence of definitive/available cardiac enzyme or electrocardiographic data, alternative enzymatic, scintigraphic, echocardiographic, angiographic, or autopsy evidence indicative of AMI; or (2) an International Classification of Diseases, 9th revision, clinical modification, discharge diagnosis code for AMI, 410.01 through 410.91.
Patients were included in this analysis if they had cardiogenic shock or if cardiogenic shock developed during hospitalization for AMI (n = 23,180). Cardiogenic shock was defined as "low blood pressure (<90 mm Hg) and signs of hypoperfusion (cool, clammy skin, oliguria, or altered sensorium), nonresponsive to fluid resuscitation or pressors."
Detailed demographic data were collected that included age, sex, race, weight, and key medical history variables (prior AMI, heart failure, percutaneous transluminal coronary angioplasty [PTCA], bypass surgery, and diabetes). Characteristics seen initially in patients included the time from symptom onset to hospital arrival, blood pressure, heart rate, and Killip class on admission. Hospital course variables included cardiac medications, interventional procedures, the location of the AMI, and the occurrence of hypotension, recurrent ischemia or infarction, pulmonary edema, cardiogenic shock, ventricular fibrillation, and death. Ejection fraction and its method of determination were recorded for those patients with known values.
Statistical methods
We compared baseline characteristics of patients with cardiogenic shock treated with and without IABP by χ 2 test for differences in categoric variables and Student t test for differences in continuous variables. To evaluate the association between patient characteristics and the use of IABP, we performed a series of multivariable logistic regression analyses with the receipt of IABP use as the dependent outcome. Factors that were statistically different (P < .05) in the univariate comparison for patients with shock, treated with and without IABP, entered into the model in a stepwise fashion, and adjusted odds ratios (OR) and 95% confidence intervals (CI) were calculated.
To evaluate the association between IABP use and hospital mortality rates independent of baseline differences in patient characteristics, we performed a series of logistic regression analyses with hospital death as the dependent variable. Factors that were associated with IABP use in the multivariate model, as well as baseline and hospital presentation factors known to be associated with death, entered the model in a stepwise fashion. The use of IABP and an interaction term of IABP with mode of reperfusion were forced into the model in the final step. Separate models were fitted for the subgroup of patients with cardiogenic shock who received thrombolytic therapy (n = 5640) and primary PTCA (n = 2925). In addition, a propensity score, reflecting the probability of receiving an IABP, was calculated for each patient who received either thrombolytic therapy or primary PTCA. 
Patient characteristics (n = 23,180)
Results
By using data from NRMI 2, we identified 23,180 patients with AMI complicated by cardiogenic shock. The baseline demographic and clinical characteristics of this population are shown in Table I . The mean age of patients in the study was 72 years, 54% were men, and the majority were white. Thirty-one percent of patients had a history of diabetes, 48% had a history of hypertension, 20% had prior angina, 20% had a history of congestive heart failure, and 28% had a history of myocardial infarction. Only 6% and 12% of patients had had a prior PTCA or coronary artery bypass graft (CABG), respectively. Of all patients who had evidence of cardiogenic shock, 25% were found to be in cardiogenic shock on arrival, whereas in the remaining patients, cardiogenic shock developed after their first physical examination. Of those patients who had cardiogenic shock, 24% received thrombolytic therapy, 15% underwent primary PTCA or immediate coronary bypass surgery, and the remaining patients received no immediate reperfusion therapy. Rescue PTCA was performed in 6.8% of patients treated with both thrombolytic therapy and IABP versus 1.7% of patients treated with thrombolytic therapy and no IABP. CABG was performed in 24.7% of patients treated with both thrombolytic therapy and IABP versus 5.5% of patients treated with thrombolytic therapy and no IABP. Of those patients who underwent primary PTCA, 10% also underwent subsequent CABG and 14% underwent a subsequent PTCA. The mean time from symptom onset to the time they received reperfusion therapy was 4.5 hours. This was in part related to a 2.2-hour delay from hospital arrival to the receipt of reperfusion therapy.
IABP was used in 7268 (31%) patients. Patients who received an IABP were on average 7 years younger and more likely to be male than patients who did not receive an IABP. They were also less likely to have a history of congestive heart failure and stroke and were more likely to have received reperfusion therapy and to have had a prior PTCA than patients who did not receive an IABP (Figure 1 and Table II) .
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Figure 1
Percentage of patients receiving either thrombolytic therapy (TT), primary angioplasty (PPTCA), or no form of reperfusion therapy (No RT) as function of whether or not they received IABP. (Table III) . Older age, female sex, and nonwhite race were associated with less IABP use. In addition, previous medical conditions including a history of a myocardial infarction, a history of congestive heart failure, and a history of diabetes mellitus were associated with less IABP use. Patients with an anterior wall myocardial infarction, those with ST-segment elevation or a left bundle branch block on their first electrocardiogram, and those who had previously received a PTCA were more likely to receive an IABP. In addition, patients who were transferred into a National Registry hospital from an outside hospital were significantly more likely to receive a balloon pump.
IABP
The overall mortality rate in all patients with cardiogenic shock was 70%. Patients who did not receive either thrombolytic therapy or primary angioplasty had a higher mortality rate (78%). Figure 2 depicts the in-hospital mortality rates for patients according to their mode of initial reperfusion therapy and whether or not they received an IABP. Patients who received thrombolytic therapy alone had a mortality rate of 67%. The mortality rate was significantly lower in patients who received thrombolytic therapy in conjunction with an IABP (49%). The mortality rate for patients treated with primary PTCA was the lowest at 42% and was slightly higher when primary PTCA was combined with IABP (47%).
The mortality rate for the cohort of patients who were found to have cardiogenic shock at the initial examination (n = 5700) was 67%, which was similar to the rate found in the overall cohort (70%). In these patients, the mortality rate was 77% for patients who did not receive thrombolytic therapy or primary angioplasty, 59% for patients receiving only a thrombolytic agent, and 53% for those receiving both a thrombolytic agent and an IABP. The rates of death for patients receiving primary PTCA and primary PTCA with IABP were 44% and 48%, respectively. Thus, patients who had cardiogenic shock at hospital arrival had mortality In-hospital mortality rates in patients who received thrombolytic therapy (TT) or primary angioplasty (PPTCA) as function of whether or not they received IABP.
rates very similar to those of patients in whom cardiogenic shock developed after hospital arrival. A multivariate model (including all the covariates noted in Table IV ) was constructed to determine the independent risk factors for death in the total cohort (n = 23,180). We observed a strong statistical interaction between the use of IABP and mode of reperfusion therapy (primary PTCA vs thrombolytic therapy; P < .001). For this reason, we repeated the multivariate model and stratified the cohort on the basis of the mode of coronary reperfusion (Table IV) . Increasing age, diabetes, prior AMI, prior CABG, increasing heart rate, and anterior myocardial infarction location were all associated with an increased mortality rate. Conversely, current smoking as well as undergoing nonimmediate revascularization with both bypass or subsequent PTCA was associated with improved survival. Although IABP use was associated with a significant reduction in mortality rates in patients treated with thrombolytic therapy (OR, 0.82; 95% CI, 0.72 to 0.93), IABP use was not associated with a reduction of mortality rates in patients treated with primary PTCA and in fact was associated with higher hospital mortality rates (OR, 1.26; 95% CI, 1.07 to 1.50). When the propensity score was included in the multivariate models, the differential effect of IABP use in patients who received thrombolytic therapy compared with patients who received primary PTCA remained unchanged.
Discussion
In this study, we made several important observations regarding the treatment and outcome of patients with AMI complicated by cardiogenic shock. First, the mortality rate in patients with cardiogenic shock remains exceedingly high (70%) and does not appear to have significantly changed over time. In a community-based study in Worcester, Massachusetts, Goldberg et al 3 found that the overall in-hospital mortality rate of patients with AMI complicated by cardiogenic shock was 78% and was constant over the study period 1975 to 1988. In this population-based study of metropolitan Worcester residents, only 7.6% of patients received thrombolytic therapy in 1988 compared with 24% in the current study. Thus, despite the more aggressive use of thrombolytic therapy, the overall mortality rate associated with cardiogenic shock appears to have decreased only slightly in the past decade.
A second important observation made in the current study is that IABP is used in only a minority of patients with AMI complicated by cardiogenic shock. However, there does appear to have been a significant increase in its use since 1988. In the study by Goldberg et al, 3 only 7.5% of patients received an IABP. The rate in the current study (study period 1994 to 1996) was 4-fold higher. Interestingly, among US-treated patients in GUSTO I (study period 1991 to 1993), the overall rate of IABP use was 32%, similar to the current study.
Third, the use of IABP in combination with thrombolytic therapy appeared to have a synergistic effect on reducing mortality rates. Although thrombolytic therapy has been demonstrated to reduce infarct size and improve survival in selected patients with AMI, there is some question as to the effectiveness of thrombolytic therapy in treating patients in cardiogenic shock. It has been suggested that impaired coronary perfusion associated with cardiogenic shock is responsible for the reduced effectiveness of thrombolytic therapy in this setting. 6, 15 For a thrombolytic agent to dissolve an occlusive coronary thrombus, the agent must bathe and then infiltrate the thrombus. 6 When mean arterial pressure falls below 65 to 70 mm Hg, coronary blood flow begins to fall and ceases to exist when mean arterial pressures drop below 30 mm Hg. 16 Several preclinical studies have demonstrated a synergistic effect of IABP and thrombolysis on establishing coronary patency. Prewitt et al 7 studied the effect of changes in aortic pressure on the efficacy of a thrombolytic agent in dogs. They found that a moderate increase in systolic blood pressure from 75 to 130 mm Hg, produced by a norepinephrine infusion, increased both the rate and extent of coronary thrombolysis. Gurbel et al 9 and Prewitt et al 8 examined the effect of arterial diastolic pressure augmentation by IABP on reperfusion after intravenous thrombolytic therapy in a canine model. They found that IABP resulted in earlier reperfusion in animals treated with r-TPA 9 and an increased rate of r-TPA-induced coronary thrombolysis. 8 Several clinical studies have suggested an improved outcome for patients with AMI complicated by cardiogenic shock who were treated with the combination of IABP and thrombolytic therapy. In one observational study involving 54 patients hospitalized with AMI, 12 who used a prospective, randomized design, tested the hypothesis that IABP would improve the late patency of the occluded coronary artery in patients with early failure of thrombolytic therapy. They found that patients treated with IABP had a significantly higher frequency of Thrombolysis In Myocardial Infarction (TIMI) flow grade 3, lower residual percent stenosis, and larger minimal lumen diameter of the infarct-related artery than did patients who did not receive IABP (74% vs 32%; 42 vs 68; and 1.6 vs 0.9 mm, respectively). The GUSTO I investigators evaluated whether IABP use was associated with lower mortality rates in patients who had evidence of cardiogenic shock at the time of hospital presentation. In this study, Anderson et al 17 identified 310 patients with AMI, in cardiogenic shock, of whom 60 (20%) received an IABP within the first 24 hours. They found that these patients had a lower unadjusted 30-day mortality rate (59% vs 48%; unadjusted P = .12) compared with patients who did not receive IABP, although this finding did not reach statistical significance. In a subsequent study, Berger et al 18 observed that an aggressive strategy of early angiography (and revascularization when appropriate) was associated with a reduction in mortality rates in patients with AMI and cardiogenic shock who receive thrombolytic therapy and that no independent benefit of IABP could be found.
The most recent evaluation of cardiogenic shock complicating AMI was the SHOCK trial, an international randomized trial of emergency PTCA/CABG versus initial medical stabilization in patients with AMI and development of cardiogenic shock. 19 Patients were randomly assigned to either emergency revascularization or initial medical stabilization. Patients in both groups then received IABP and pharmacologic support. Patients randomly assigned to initial medical stabilization were required to receive thrombolytic therapy unless there was an absolute contraindication and then underwent delayed PTCA or CABG >54 hours later. At 30 days, the all-cause mortality rate was 46% in the emergency revascularization group versus 56% in the initial medical stabilization group (P = .11). One explanation for why the SHOCK trial did not demonstrate the expected 20% reduction in mortality rates with emergency revascularization compared with initial medical stabilization was that there was a lower than expected mortality rate in the initial medical stabilization arm. Data from the current study would suggest that the lower than expected mortality rate in the patients with initial medical stabilization may have resulted from the very intensive medical treatment with IABP and thrombolytic therapy.
Observations from the current analyses support numerous previous clinical and preclinical studies that suggest that IABP enhances the effectiveness of thrombolytic therapy in patients with AMI complicated by cardiogenic shock. Specifically, our results suggest that treatment with both IABP and thrombolytic therapy is associated with an improvement in hospital survival compared with treatment with thrombolysis alone. After adjusting for baseline differences between patients who did and those who did not receive IABP, we found that receiving an IABP was associated with an 18% (adjusted OR, 0.82; 95% CI, 0.72 to 0.93) reduction in hospital mortality rates in patients treated with thrombolytic therapy. Interestingly, there was no associated benefit with the use of IABP in patients treated with primary PTCA, a treatment modality that does not rely on coronary perfusion pressure to establish patency. 20 
Limitations
There are several limitations of the current analysis. First, although we included data from more than 1400 hospitals throughout the United States, these hospitals may not be completely reflective of all US hospitals. 21 Participating registry centers tend to be larger, more procedure-oriented, and more likely to use reperfusion therapy than nonparticipating hospitals. Second, data obtained on each enrolled patient are limited to his or her in-hospital stay. Third, there is no independent onsite validation of data forms and thus there exists the potential for nonconsecutive patient enrollment. However, recent work from Every et al 14 suggests that the data abstraction process used in NRMI 2 is comparable to the more rigorous processes used in the Cooperative Cardiovascular Project. Fourth, the exact timing of IABP placement was not collected in the current study; therefore one cannot exclude the possibility that the beneficial effect seen with IABP was related to survivor bias. Finally, although the information was collected prospectively, this analysis is retrospective and as such has many of the limitations associated with this type of clinical research, including nonrandom allocation of treatment with IABP.
Conclusions
Numerous studies have convincingly shown that patency of the infarct-related artery is of paramount importance in patients with AMI. This appears to be particularly true in patients with cardiogenic shock. Data from the current study suggest that patients with AMI complicated by cardiogenic shock may have sub-stantial benefit from the combination of thrombolytic therapy and IABP. However, because this study is observational in nature, it is not definitive. Only a properly designed randomized, controlled trial can accurately answer this important question. One such study, the TACTICS trial, is currently enrolling patients and should provide an answer soon.
